carried out to establish the serotype specificity of the antibodies.
6.
We have described some auxiliary assays for the confirmation of positive C.ELISA-I results. The testing of samples with values of 150 in the C.ELISA-I by at least 1 of the other ELISA formats, a competitive assay using the ATCC MAb and/or a blocking assay using the Pirbright MAb, reduces the number of sera referred for confirmatory MTSN testing. Luis Ferrer, Dolors Fondevila, Rosa Rabanal, Jordi Tarres, Antonio Ramis Lymphoma, with an incidence of 24 cases per 100,000 dogs, is the third most common neoplasia in dogs. 5 Although in recent years considerable advances have been made in the diagnosis and treatment of canine lymphoma, the histogenesis and the immunologic characteristics of the proliferating cells are not completely understood. Some studies using immunofluorescence techniques or cytofluorographic analysis reported that most canine lymphomas originate from B lymphocytes, although no definitive results were obtained. 7 ' 9 The identification of the immunophenotype of canine lymphomas is important not only for a better understanding of thebiology of this neoplasm but also because some canine im-munophenotypes (T-cell lymphomas) have shorter survival times. 7 A wide range of well-characterized reagents directed at human lymphocyte surface markers are used to immunophenotype human lymphomas, but the vast majority of these do not cross-react with canine lymphocyte surface markers? Unfortunately, very few monoclonal antibodies have been developed for dogs, 12, 13, 19 and these monoclonal antibodies only work on frozen tissue and do not react with formalinfixed, paraffin-embedded sections.
Immunohistochemical detection of CD3 antigen (pan T marker) in canine lymphomas
Recently, a polyclonal antibody has been developed that is directed against a sequence of the human CD3 molecule that is resistent to formalin fixation and paraffin embedment. 11 The CD3 molecule is associated with the T-cell receptor and transmits the activation signal to the cytoplasm. Extensive studies in human beings have demonstrated that the CD3 molecule is restricted in its expression to T-lym- Table 1 . Immunoreactivity for CD3 antigen in canine lymphomas. phoid cells, with the possible exception of Purkinje cells in the cerebellum. 11 Furthermore, for the diagnosis of lymphomas in routine fixed material, CD3 is an excellent marker because it is retained following neoplastic transformation. 4, 8 This polyclonal antibody also reacts with canine T lymphocytes in paraffin-embedded sections?
The purpose of this study was to investigate the presence of CD3 antigen in canine lymphomas, to better understand the histogenesis of this neoplasm, and to develop a simple and reliable technique for immunophenotyping canine lymphomas in routine material.
Ninety-nine cases of canine lymphoma have been studied. Seventy cases were diagnosed as multicentric lymphomas (primarily nodal), 14 as nonepidermotropic cutaneous lymphomas (extranodal lymphomas), and 15 as epidermotropic cutaneous lymphomas (mycosis fungoides). In all cases, the diagnosis was made after clinical evaluation of the disease and histopathologic study of tissue samples. Only cases with a definitive histopathologic diagnosis, confirmed by clinical evaluation, were included in this study. Biopsy specimens were fixed in buffered 10% formalin, embedded in paraffin, sectioned at 4 µm, and stained with hematoxylin and eosin for histopathologic evaluation. All cases were classified according to the National Cancer Institute Working Formulation, modified for the dog. 3 The immunohistochemical demonstration of the CD3 antigen was performed using the peroxidase-antiperoxidase method. 6 The paraffin sections were treated with pronase a 0.1% in Tris buffer for 10 minutes at room temperature and incubated with the CD3 polyclonal antiserum b (1:300, 18 hours at 4 C). The sections were then incubated with a goat anti-rabbit IgG serum C (1: 100) and finally with a rabbit peroxidase-antiperoxidase complex c (1: 200) . After the application of the pronase and the sequential incubations, the sections were rinsed 3 times for 10 minutes in Tris buffer. The immunologic reaction was developed with diaminobenzidine. a Sections were counterstained with hematoxylin, dehydrated, and mounted in DPX. d The positive controls were paraffin-embedded sections of a human lymph node, a canine lymph node, and a canine tonsil. The negative controls were sections incubated in normal rabbit serum in place of specific CD3 antiserum.
In the normal canine control tissues the lymphocytes in the T-cell areas reacted with the anti-CD3 antibody. The reaction was intense and limited to the cell membrane. 6 The sections incubated with normal rabbit serum instead of the primary antibody were clearly negative. The immunohistochemical results of the lymphomas are presented in Table 1 . A complete description of the various morphologic categories of canine lymphomas according to the Working Formulation was published previously, 2 and therefore only the prevalence of each lymphoma type and the immunohistochemical results are given ( Table 2 ).
The diffuse large-cell lymphoma (centroblastic; Kiel classification) was the most common type of lymphoma encountered in the study. Some large-cell lymphomas were intensively CD3 positive (over 90% of proliferating cells being positive) ( Fig. 1 ). The remaining lymphomas were composed of cells that were clearly CD3 negative (Fig. 2 ). In the lymphomas considered CD3 negative, it was always possible to detect nonneoplastic CD3-positive lymphocytes. The specificity of the immunoreaction was confirmed by the presence of nonneoplastic CD3-positive lymphocytes within the CD3-negative lymphomas (Fig. 2) .
The diffuse mixed lymphoma (centroblastic-centrocytic; Kiel) was the second most common type, with an immunoreactivity pattern similar to that of the diffuse large-cell lymphomas. Some of these tumors were clearly CD3 positive, and the remaining were completely CD3 negative.
The small lymphocytic lymphoma (lymphocytic; Kiel) group contained 7 tumors of the lymphoplasmacytoid subtype. The lymphocytic lymphomas, except for 1 case, were all consistently CD3 negative. Some CD3-positive cells could be seen in the remnant lymphoid tissue.
The immunoblastic lymphoma (immunoblastic; Kiel) group were of the immunoblastic type, and all were consistently CD3 negative.
The lymphoblastic lymphoma (T-lymphoblastic; Kiel) group, composed of 7 tumors, contained 6 intensely CD3positive and 1 negative multicentric lymphoma.
The follicular lymphomas (centroblastic, centroblasticcentrocytic; Kiel) group was composed of 4 lymphomas that were all multicentric. One tumor was a large-cell follicular lymphoma, and the other 3, composed of mixed small, cleaved, and large cells, were diagnosed as follicular mixed cell lymphomas. All tumors were consistently CD3 negative.
The diffuse, small noncleaved-cell lymphoma (B-lymphoblastic; Kiel) group was composed of 3 multicentric lymphomas that were clearly CD3 negative.
The epitheliotropic lymphoma (mycosis fungoides) group contained 15 cases in which the proliferating cells were intensively CD3 positive (Fig. 3) .
None of the lymphomas were assigned to the categories of follicular small cleaved cell or diffuse small cleaved cell.
The prevalence of the different types of lymphomas in this series is similar to that published recently. 7 The minor differences, for instance the higher incidence of diffuse mixedcell lymphomas in the present series, are probably a consequence of the application of different criteria when classifying the cells. The problem of different criteria is frequently found in the diagnosis of lymphoma in human beings. 2 The other small discrepancies could be due to geographical (ambiental) or genetic factors, as has been documented for human beings. 10 The results indicate that approximately 27% of canine multicentric lymphomas are CD3 positive and probably originate from T cells. This finding is similar to the percentage of non- Hodgkin's lymphomas that originate from T lymphocytes in human beings 16 and is also in concordance with results previously published, 9 in which surface immunoglobulins were detected in 11 of 16 examined lymphomas. These workers considered most canine lymphomas to originate from B lymphocytes. 9 In another study of 12 T-cell lymphomas, these lymphomas were commonly associated with hypercalcemia and showed a low complete response rate to chemotherapy with shortened remission and survival times. 7 One of the major difficulties of the Working Formulation is that the classification is based on clinicopathologic criteria. Consequently, different immunophenotypes are included in the same category. 4, 10, 15 This difficulty is well known in the case of human non-Hodgkin's lymphoma and in bovine viral leukosis. l8 The diffuse large-cell lymphomas (centroblastic) and diffuse mixed cell lymphomas (centroblasticcentrocytic) in human beings are immunologically heterogeneous groups of lymphomas, which tend to be derived from B cells. In the dog, large-cell lymphomas are probably also a heterogeneous group of lymphomas; strongly CD3-positive (probably T-cell origin) and numerous CD3-negative cases have been found. The small lymphocytic lymphoma in human beings is well characterized as a B-cell lymphoma. According to the results of the present study, the B cell is also the most probable cell of origin in the dog. Only in 1 out of 13 multicentric lym- phomas could CD3 antigen be detected immunohistochemically in the proliferating cell population, possibly because of an intense infiltration by T cells of an original B-cell lymphoma (the so-called T-cell-rich B-cell lymphoma of human beings), an aberrant expression of the antigen by neoplastic B lymphocytes, or an error in the histologic classification of the lymphoma. In human beings, immunoblastic lymphomas are divided in 4 subtypes (plasmacytoid, clear cell, polymorphous, and immunoblastic with epithelial components), and most of them originate from B lymphocytes. According to the present findings, canine immunoblastic lymphomas are consistently CD3 negative and probably originate from B cells, as are follicular lymphomas (centroblastic, centroblastic-centrocytic) and diffuse, small noncleaved-cell lymphomas (B-lymphoblastic). In humans, lymphoblastic lymphomas (T-lymphoblastic; Kiel) have been associated with the T-cell phenotype, presentation in young males, the presence of a mediastinal mass, and hypercalcemia. Most of the canine lymphoblastic lymphomas (6 out of 7 cases investigated) were strongly CD3 positive and had a T-cell origin. Similar results were published previously; 3 alpha-naphthylacetate esterase activity was found in most canine lymphoblastic lymphomas, indicating a T-cell origin.
A high percentage of cutaneous lymphomas are CD3 positive. As expected, all investigated cases of mycosis fungoides were strongly CD3 positive, confirming a T-cell origin. In human mycosis fungoides, the proliferating cells are T lymphocytes that express the immunophenotype CD4 + (T-helper lymphocyte). 4, 10 In the dog, recent reports suggest that proliferating cells may be CD8 + . 13 Most authors consider that canine cutaneous nonepidermotropic lymphomas have a B-cell origin, despite the lack of published data. 14, 20 The present results indicate that canine cutaneous nonepidermotropic lymphoma is a morphologically and immunologically heterogeneous group of lymphomas. Of the 14 cases studied, 8 were of the diffuse large-cell type, 3 were of the diffuse mixed-cell type, and there was 1 case from each of the small lymphocytic, immunoblastic, and lymphoblastic groups. Large-cell lymphoma is also the most prevalent type of cutaneous nonepidermotropic lymphoma in humans. 4 The percentage of CD3-positive neoplasms in the present series is higher, 8 out of 14 (57%), suggesting that the T-cell immunophenotype is more common among extranodal neoplasms. This finding is similar to reports for humans. In human medicine, peripheral T-cell lymphomas, other than the well-known clinicopathologic entities of mycosis fungoides and Sezary's syndromes, have received a great deal of attention. They are difficult to classify, differ widely in their clinical presentation, and behave unpredictably. There are no available data about the behavior of these lymphomas in dogs.
To immunophenotypically characterize canine lymphomas, a broad panel of antibodies would be required for analysis. The method using the CD3 antibody could be useful to the veterinary pathologist in the diagnosis and classification of canine lymphoproliferative diseases because this technique can be performed on routine histopathologic sections.
It is also important to consider whether it is really useful to use the same approach to canine lymphoma that researchers in human medicine do. Advances in immunologic and molecular diagnosis and use of special techniques have led to numerous reports of new forms of human non-Hodgkin's lymphoma. In some cases, well-recognized entities have been characterized (e.g., enteropathy-associated T-cell lympho-ma), but others are of more uncertain significance (e.g., T-cellrich B-cell non-Hodgkin's lymphoma and anaplastic Ki-1positive large-cell lymphoma), and many clinicians are very skeptic about the potential usefulness of these subdivisions and feel that this complexity in the classification may be confusing. 2 Veterinary medicine is not as advanced as human medicine in this area because a broad correlation between morphology or immunophenotype and prognosis still must be documented. The different morphologic and immunologic types may be only an epiphenomenon, with no clinical meaning. All too often, clinicians and pathologists work separately and with different goals. These tumors must be understood at a immunological and molecular level, but the pathologist should not forget the clinical applications of the new techniques. Clinicians and pathologists should collaborate in wellconstructed clinical studies to verify the clinical validity of any technique or of any subgroup that may emerge.
